Susanne Stera1, Panagiotis Balermpas2,3, Mark K H Chan4, Stefan Huttenlocher5, Stefan Wurster5,6, Christian Keller2,3, Detlef Imhoff2, Dirk Rades7, Jürgen Dunst4,8, Claus Rödel2, Guido Hildebrandt9, Oliver Blanck3,4,5. 1. Department of Radiation Oncology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. susanne.stera@kgu.de. 2. Department of Radiation Oncology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. 3. Saphir Radiosurgery Center, Frankfurt, Germany. 4. Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany. 5. Saphir Radiosurgery Center, Güstrow, Germany. 6. Department of Radiation Oncology, University Medicine Greifswald, Greifswald, Germany. 7. Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany. 8. Department of Radiation Oncology, University Hospital Copenhagen, Copenhagen, Denmark. 9. Department of Radiation Oncology, University Medicine Rostock, Rostock, Germany.
Abstract
PURPOSE: We retrospectively evaluated the patterns of failure for robotic guided real-time breathing-motion-compensated (BMC) stereotactic body radiation therapy (SBRT) in the treatment of tumors in moving organs. PATIENTS AND METHODS: Between 2011 and 2016, a total of 198 patients with 280 lung, liver, and abdominal tumors were treated with BMC-SBRT. The median gross tumor volume (GTV) was 12.3 cc (0.1-372.0 cc). Medians of mean GTV BEDα/β =10 Gy (BED = biological effective dose) was 148.5 Gy10 (31.5-233.3 Gy10) and prescribed planning target volume (PTV) BEDα/β =10 Gy was 89.7 Gy10 (28.8-151.2 Gy10), respectively. We analyzed overall survival (OS) and local control (LC) based on various factors, including BEDs with α/β ratios of 15 Gy (lung metastases), 21 Gy (primary lung tumors), and 27 Gy (liver metastases). RESULTS: Median follow-up was 10.4 months (2.0-59.0 months). The 2‑year actuarial LC was 100 and 86.4% for primary early and advanced stage lung tumors, respectively, 100% for lung metastases, 82.2% for liver metastases, and 90% for extrapulmonary extrahepatic metastases. The 2‑year OS rate was 47.9% for all patients. In uni- and multivariate analysis, comparatively lower PTV prescription dose (equivalence of 3 × 12-13 Gy) and higher average GTV dose (equivalence of 3 × 18 Gy) to current practice were significantly associated with LC. For OS, Karnofsky performance score (100%), gender (female), and SBRT without simultaneous chemotherapy were significant prognostic factors. Grade 3 side effects were rare (0.5%). CONCLUSIONS: Robotic guided BMC-SBRT can be considered a safe and effective treatment for solid tumors in moving organs. To reach sufficient local control rates, high average GTV doses are necessary. Further prospective studies are warranted to evaluate these points.
PURPOSE: We retrospectively evaluated the patterns of failure for robotic guided real-time breathing-motion-compensated (BMC) stereotactic body radiation therapy (SBRT) in the treatment of tumors in moving organs. PATIENTS AND METHODS: Between 2011 and 2016, a total of 198 patients with 280 lung, liver, and abdominal tumors were treated with BMC-SBRT. The median gross tumor volume (GTV) was 12.3 cc (0.1-372.0 cc). Medians of mean GTV BEDα/β =10 Gy (BED = biological effective dose) was 148.5 Gy10 (31.5-233.3 Gy10) and prescribed planning target volume (PTV) BEDα/β =10 Gy was 89.7 Gy10 (28.8-151.2 Gy10), respectively. We analyzed overall survival (OS) and local control (LC) based on various factors, including BEDs with α/β ratios of 15 Gy (lung metastases), 21 Gy (primary lung tumors), and 27 Gy (liver metastases). RESULTS: Median follow-up was 10.4 months (2.0-59.0 months). The 2‑year actuarial LC was 100 and 86.4% for primary early and advanced stage lung tumors, respectively, 100% for lung metastases, 82.2% for liver metastases, and 90% for extrapulmonary extrahepatic metastases. The 2‑year OS rate was 47.9% for all patients. In uni- and multivariate analysis, comparatively lower PTV prescription dose (equivalence of 3 × 12-13 Gy) and higher average GTV dose (equivalence of 3 × 18 Gy) to current practice were significantly associated with LC. For OS, Karnofsky performance score (100%), gender (female), and SBRT without simultaneous chemotherapy were significant prognostic factors. Grade 3 side effects were rare (0.5%). CONCLUSIONS: Robotic guided BMC-SBRT can be considered a safe and effective treatment for solid tumors in moving organs. To reach sufficient local control rates, high average GTV doses are necessary. Further prospective studies are warranted to evaluate these points.
Authors: R J Klement; M Guckenberger; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; D Habermehl; G Hildebrandt; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; N Andratschke Journal: Radiother Oncol Date: 2017-03-06 Impact factor: 6.280
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer Journal: Strahlenther Onkol Date: 2013-09-21 Impact factor: 3.621
Authors: Anthony Ricco; Joanne Davis; William Rate; Jun Yang; David Perry; John Pablo; David D'Ambrosio; Sanjeev Sharma; Srinath Sundararaman; James Kolker; Kimberly M Creach; Rachelle Lanciano Journal: Radiat Oncol Date: 2017-02-01 Impact factor: 3.481
Authors: K J Borm; M Oechsner; K Schiller; J C Peeken; H Dapper; S Münch; L Kroll; S E Combs; M N Duma Journal: Strahlenther Onkol Date: 2018-07-16 Impact factor: 3.621
Authors: Maria-Lisa Wilhelm; Mark K H Chan; Benedikt Abel; Florian Cremers; Frank-Andre Siebert; Stefan Wurster; David Krug; Robert Wolff; Jürgen Dunst; Guido Hildebrandt; Achim Schweikard; Dirk Rades; Floris Ernst; Oliver Blanck Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621
Authors: Kerstin A Kessel; Rebekka C E Grosser; Kim Melanie Kraus; Hans Hoffmann; Markus Oechsner; Stephanie E Combs Journal: BMC Cancer Date: 2020-05-19 Impact factor: 4.430
Authors: Paul Aridgides; Tamara Nsouli; Rishabh Chaudhari; Russell Kincaid; Paula F Rosenbaum; Sean Tanny; Michael Mix; Jeffrey Bogart Journal: Lung Cancer (Auckl) Date: 2018-11-05
Authors: Khaled Bousabarah; Oliver Blanck; Susanne Temming; Maria-Lisa Wilhelm; Mauritius Hoevels; Wolfgang W Baus; Daniel Ruess; Veerle Visser-Vandewalle; Maximilian I Ruge; Harald Treuer; Martin Kocher Journal: Radiat Oncol Date: 2021-04-16 Impact factor: 3.481
Authors: Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Front Oncol Date: 2018-05-17 Impact factor: 6.244